ReviewPublished 30 April 2026From biosimilars to breakthroughs: regulatory convergence toward evidence-efficient development of monoclonal antibodiesSarfaraz K. NiaziFrontiers in Drug Discoverydoi 10.3389/fddsv.2026.1778468
ReviewPublished 15 April 2026Analytical similarity as the primary determinant of monoclonal antibody development: toward evidence-efficient regulatory frameworksSarfaraz K. NiaziFrontiers in Drug Deliverydoi 10.3389/fddev.2026.1801236
